Trial Profile

A one-year, Phase II, randomized, double-blind, placebo-controlled, safety and efficacy trial of edasalonexent in non-ambulatory boys and men affected by Duchenne Muscular Dystrophy

Status: Planning

Phase of Trial: Phase II

Latest Information Update: 26 Jul 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

10 Aug 2020 According to a Catabasis Pharmaceuticals media release, the the trial is expected to initiate in 2021.
10 Jan 2020 New trial record
08 Jan 2020 According to a Catabasis Pharmaceuticals media release, the company has entered into a collaboration with Duchenne UK to conduct this trial. Duchenne UK has granted over $600,000 in funding to support patient and clinical trial site costs for this trial. The company intends that upon completing this trial, patients will have the option to transition to the GalaxyDMD open-label extension trial and receive edasalonexent.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com